Efficacy and safety of Creon® 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis☆
To access this article, please choose from the options below
☆ Previously presented at Digestive Disease Week, May 30–Jun 04, 2009, Chicago, IL, USA, and the 32nd European Cystic Fibrosis Society Conference, June 10–13, 2009, Brest, France.
PII: S1569-1993(09)00122-2
doi:10.1016/j.jcf.2009.08.008
© 2009 European Cystic Fibrosis Society. Published by Elsevier Inc All rights reserved.
